secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bausch & Lomb Corp (BLCO)
CIK:        0001860742
Form:       8-K
Filed at:   2023-06-30T23:59:59+00:00
Accession:  0001193125-23-179447
Event type: m_and_a
Sentiment:  positive
Materiality: 0.85
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bausch + Lomb agrees to acquire XIIDRA from Novartis for up to $2.5B
--------------------------------------------------------------------

- Upfront cash $1.75B plus up to $750M in milestones; total consideration up to $2.5B.
- XIIDRA generated ~$487M in sales in 2022; patented through 2033.
- Acquisition includes libvatrep (Phase 2b) and AcuStream device.
- Expected close by end of 2023; immediately accretive; J.P. Morgan committed financing.
- B+L expects to return to current leverage within ~24 months post-close.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1860742/000119312523179447/0001193125-23-179447-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1860742/000119312523179447/d493799d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-179447

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer